Show simple item record

dc.contributor.authorStrehlitz, Anja
dc.contributor.authorGoldmann, Oliver
dc.contributor.authorPils, Marina C
dc.contributor.authorPessler, Frank
dc.contributor.authorMedina, Eva
dc.date.accessioned2018-11-28T10:27:41Z
dc.date.available2018-11-28T10:27:41Z
dc.date.issued2018-01-01
dc.identifier.issn1664-3224
dc.identifier.pmid29988532
dc.identifier.doi10.3389/fimmu.2018.01424
dc.identifier.urihttp://hdl.handle.net/10033/621590
dc.description.abstractStreptococcus pneumoniae is the most common cause of community-acquired pneumonia (CAP). Despite the low prevalence of CAP caused by methicillin-resistant Staphylococcus aureus (MRSA), CAP patients often receive empirical antibiotic therapy providing coverage for MRSA such as vancomycin or linezolid. An early differentiation between S. pneumoniae and S. aureus pneumonia can help to reduce the use of unnecessary antibiotics. The objective of this study was to identify candidate biomarkers that can discriminate pneumococcal from staphylococcal pneumonia. A genome-wide transcriptional analysis of lung and peripheral blood performed in murine models of S. pneumoniae and S. aureus lung infection identified an interferon signature specifically associated with S. pneumoniae infection. Prediction models built using a support vector machine and Monte Carlo cross-validation, identified the combination of the interferon-induced chemokines CXCL9 and CXCL10 serum concentrations as the set of biomarkers with best sensitivity, specificity, and predictive power that enabled an accurate discrimination between S. pneumoniae and S. aureus pneumonia. The predictive performance of these biomarkers was further validated in an independent cohort of mice. This study highlights the potential of serum CXCL9 and CXCL10 biomarkers as an adjunctive diagnostic tool that could facilitate prompt and correct pathogen-targeted therapy in CAP patients.en_US
dc.publisherFrontiersen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectStaphylococcus aureusen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectbiomarkersen_US
dc.subjectinterferonen_US
dc.subjectpneumoniaen_US
dc.subjecttranscriptomeen_US
dc.titleAn Interferon Signature Discriminates Pneumococcal From Staphylococcal Pneumonia.en_US
dc.typeArticleen_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.; TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.en_US
refterms.dateFOA2018-11-28T10:27:41Z
dc.source.journaltitleFrontiers in immunology


Files in this item

Thumbnail
Name:
Strehlitz et al.pdf
Size:
2.383Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States